Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rebif interferon beta-1a autoimmune data

In the international REGARD study in 764 patients, Rebif failed to significantly improve the time

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE